This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


Ofatumumab

From Proteopedia

Revision as of 07:31, 14 December 2010 by David Canner (Talk | contribs)
Jump to: navigation, search

Ofatumumab, better known as Arzerra, (3giz)

Drag the structure with the mouse to rotate

Better Known as: Arzerra

  • Marketed By: Genmab & GlaxoSmithKline
  • Major Indication: Chronic Lymphocytic Leukemia
  • Drug Class: Anti-CD20 Monoclonal Antibody
  • Date of FDA Approval: 2009 (2023)
  • 2009 Sales: $3.1 Billion
  • See Pharmaceutical Drugs for more information about other drugs and diseases.

Mechanism of Action

References


Proteopedia Page Contributors and Editors (what is this?)

David Canner, Joel L. Sussman

Retrieved from "http://52.214.119.220/wiki/index.php/Ofatumumab"
Personal tools